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1. Introduction
The field of schistosomiasis vaccine has suffered from several entrenched dogmas, which
have delayed progress.
The first dogma states that the main mechanism of innate and acquired immunity-related
parasite attrition is antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC has been
shown to effectively mediate killing of 3-, 18- or 24 hr-old schistosomula in human, mouse,
and rat models. However, this phenomenon is of no in vivo relevance as larvae of this age
are still in the epidermis, impervious to host immune attacks. Intact, healthy older larvae,
pre-adults and adult schistosomes are entirely invisible to the immune system, and thus, are
never threatened by ADCC in vitro or in vivo. Concurrently, the immune effectors “hunt”
for larvae in the pulmonary capillaries, proposed by von Lichtenberg et al. in 1977 [1] as a
plausible mechanism for resistance to infection, was entirely neglected, and never men‐
tioned or referred to.
Second dogma is to consider parasite surface membrane antigens of great importance as
vaccine antigens, because they reside at the host-parasite interface, and were shown to in‐
duce robust immune responses. However, schistosome surface membrane molecules are
hidden, inaccessible to host antibodies, and accordingly, induced immune effectors are un‐
able to interact with the parasite.
Third,  stressing  that  Th1  immune  responses  are  the  pillars  for  acquired  immunity  to
larval  infection  in  mice.  This  dogma  is  entrenched  notwithstanding  the  numerous  re‐
ports documenting the importance of exclusive type 2 immune responses in rat, monkey,
and human schistosomiasis, and despite that larval antigens induce principally Th1 relat‐
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ed  cytokines  and  antibodies  that  are  not  entirely  protective  in  mice.  Enhancement  of
these  Th1  responses  during  mouse  immunization,  via  the  use  of  Th1-biased  constructs
and  adjuvants,  consistently  elicited  only  partial  resistance,  with  candidate  vaccine  anti‐
gens discarded one after the other.
This review aims to dispel these dogmas and opens a new avenue for the development of a
remedy and vaccine for schistosomiasis.
2. Body
2.1. Schistosomiasis
Schistosomiasis, also known as bilharziosis, bilharzia, or snail fever, is endemic in 74 coun‐
tries of the Developing World, infecting between 391 and 600 million people worldwide.
with close to 800 million, mostly children, at risk [2,3]. The disease burden is estimated to
exceed 70 million disability-adjusted life-years [4]. The causative agents are flatworms, dioe‐
cious (separate sex) trematodes, of the family Schistosomatidae, with Schistosoma mansoni
and Schistosoma haematobium responsible for the largest numbers of human infections. The
infective stage, the cercaria, invades host skin, and stays in the blood- and lymph-free epi‐
dermis for a minimum of 40 and up to 72 hr, impervious to innate immunity effectors [5,6].
The parasite develops into a schistosomulum, exchanging the classical outer membrane for a
double lipid bilayer covering [7], and releasing in the process of physiological and biochemi‐
cal changes numerous enzymes and other molecules, which may interact with the innate im‐
munity receptors on keratinocytes and Langerhans cells [4,8-11]. The innate immunity cells
proceed to activation of the acquired immune system, and produce cytokines that shape the
amount and direction of the adaptive immune responses to the developing parasite [4,8-10].
Schistosomula then penetrate dermal blood vessels, and remain intravascular for their life
span, and therefore, schistosomes of the genus Schistosoma are known as blood flukes [12].
The schistosomula travel via the pulmonary artery reaching the lungs within 4-6 and 6-10
days for S. mansoni and S. haematobium, respectively [13], painstakingly negociate the lung
capillaries, then migrate to the hepatic portal vessels, where they start to actively feed, ma‐
ture, and copulate. It is important here to recall that developing (and mature) schistosomes
live in the blood vessels and capillaries, and hence, released, excreted, or secreted molecules
are blood-borne products, which likely access macrophages, dendritic cells, and B cells in
the spleen rather than the lung tissue draining lymph nodes. It is documented that develop‐
ing schistosomula products elicit predominant T helper (Th) Th1 and Th17 immune re‐
sponses, dominated by interferon-gamma (IFN-g) and interleukin (IL)-17, and IgG2a and
IgG2b antibodies [14-19]. The male carrying the female in the gynaecophoric groove, the
schist, then migrates to the mesenteric venules (S. mansoni) or the vesical capillaries around
the urinary bladder (S. haematobium). Hundreds of eggs are deposited daily. Eggs exit the
host via the intestine with the feces (S. mansoni) or the urinary bladder, with the urine (S.
haematobium) to continue the life cycle in compatible snails [12,20]. Numerous eggs are re‐
tained in the host tissue, inciting intense immune responses to the parasite egg antigens,
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characterized by granulomas formation around the eggs and progressive liver (S. mansoni)
or urinary bladder (S. haematobium) tissue damage and fibrosis [21], and dominated by Th2
cytokines [14,15].
Skewing of the immune responses of patently infected hosts towards the Th2 axis may be
the reason whereby infection with schistosomes increases the severity of subsequent infec‐
tion with other pathogens namely Plasmodium falciparum, Leishmania, Toxoplasma gondii, My‐
cobacteria, Entamoeba histolytica, Staphylococcus aureus, or Salmonella [22, and references
therein]. Schistosomiasis also may predispose individuals to infection with human immuno‐
deficiency (HIV) and hepatitis C (HCV) virus, and increases resulting disease persistence
and severity [2,23,24]. Individuals with schistosomiasis haematobium are at great risk for
HIV infection, and for cancer development [24,25], afflictions all requiring robust Th1 re‐
sponses for control and elimination [26].
2.2. Control
2.2.1. Molluscicides
Schistosome species require 2 hosts, a definitive mammalian and an intermediate freshwater
snail host, for completion of the life cycle. Schistosoma mansoni and S. haematobium eggs re‐
lease the miracidium, which must find a snail of the genus Biomphalaria and Bulinus, respec‐
tively for asexual reproduction, whereby infection of a compatible snail with a single
miracidium results in production of thousands of infective cercariae [12,20]. The prevalence
of schistosomiasis is linked to compatible snail distribution. Accordingly, breaking the
dreadful cycle may well be accomplished via elimination of the obligatory intermediate
snail host.
Snails of the Biomphalaria and Bulinus spp. live under water, and all molluscicidal measures
must take into account vegetation, fish, ducks, and other animals habitat, as well as water
quality for drinking and irrigation, rendering control of snails with chemicals, such as acro‐
lein, copper sulfate, and niclosamide, a particularly costly approach [2,27].
2.2.2. Sanitation and health education
People acquire schistosomiasis while farming, fishing, bathing, washing, and performing
recreational activities in the vicinity of water bodies contaminated with infected snails. Ac‐
cordingly, safe water supply, improved sanitation, and health education are mandatory in
order to effectively reduce (and eventually eliminate) the very significant global burden of
disease due to schistosomiasis and other helminthic parasites, yet are unavailable in numer‐
ous countries due to poor economical, social, and political conditions [2-4].
2.2.3. Praziquantel
Praziquantel (PZQ), a pyrazino-isoquinoline derivative, FW 312.41, is practically now the
single cost-affordable, and relatively safe and effective oral drug for mass treatment of hun‐
dreds of millions of individuals afflicted with schistosomiasis mansoni, schistosomiasis hae‐
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matobium, and schistosomiasis japonicum as well [2-4,21]. Due to its hydrophobic nature
and small size, PZQ inserts itself into the parasite outer lipid bilayer membrane, leading to
its vacuolization, blebbing, and disruption [28]. Several reports documented the ability of
PZQ to bind and polymerise actin [29-34]. Actin-based membrane skeleton (the fence) lies
beneath the inner leaflet of the plasma membrane [35], and accordingly PZQ-parasite actin
binding and subsequent polymerization may explain the severe muscle contraction and the
paralysis worms undergo immediately upon exposure in vitro to PZQ. This mode of action,
if proven to be true, suggests that PZQ treatment might not be entirely safe for children, per‐
sons with cardiovascular afflictions, and pregnant women [36].
Even if absolutely and entirely safe, PZQ treatment is not 100% proof and does not prevent
reinfection or diminishes prevalence [37], necessitating periodic examination and repeated
treatments, and thus, exacerbating the possiblity of the emergence of parasite resistance to
the drug, a threat that has already materialized in several settings [38,39].
2.2.4. Vaccine status − Documented target: The lung-stage schistosomula
The hope for development of a schistosomiasis vaccine stems from the strong, and reprodu‐
cible, protective immunity obtained after immunization of experimental hosts with radia‐
tion-attenuated (RA) cercariae [1,40], and the documented human resistance to infection
(endemic normals), or reinfection after chemotherapy [41-43]. Sera and spleen cells of RA-
vaccinated, and worm antigens-protectively immunized mice were used for identification of
the potential protective target antigens. These studies resulted in identification, cloning,
gene expression and assessment of protective potential of a plethora of molecules, among
which S. mansoni irradiation associated vaccine antigen, IrV-5 [44], glutathione-S-transferase,
GST [45], triose phosphate isomerase, TPI [46,47], paramyosin [48], fatty acid binding pro‐
tein, Sm 14 [49], the surface membrane antigen Sm23 [50], the calcium-dependent cysteine
protease, calpain [51], enolase [52,53], and calreticulin [54-56]. Reactivity of serum antibodies
and peripheral blood mononuclear cells of resistant humans with fractionated worm mole‐
cules succeeded in identification of S. mansoni glyceraldehyde 3-phosphate dehydrogenase
[57-61] as a potential candidate vaccine antigen. These molecules were used in conjunction
with different adjuvants, namely complete (CFA) and incomplete (IFA) Freund’s adjuvant
for mouse immunization, leading to only hardly significant (P < 0.05) of some 30-35% reduc‐
tion of challenge worm burden. Except for Sm23, these molecules are all cytosolic, and the
poor protective capacity was ascribed to their inability to interact with the host immune sys‐
tem effector molecules.
Sm 23, an outer S. mansoni surface membrane antigen was among the molecules thought to
be a target of protective immunity and of potential importance due to its residence at the
host-parasite interface [50]. The full length molecule in a plasmid or recombinant form failed
to lead to highly significant, consistent, or reproducible protection despite of their use in
combination with a number of different adjuvants [62-64]. The S. mansoni integral surface
membrane proteins tetraspanins (TSP)-1 and TSP-2 encoding cDNA were cloned, se‐
quenced, and expressed and shown to elicit protection levels of 57% and 64% (TSP-2) and
34% and 52% (TSP-1) for mean adult worm burdens and liver egg burdens, respectively,
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over two independent trials in CBA/CaH mice [65]. The protection levels were not repro‐
duced using S. japonicum counterpart, whereby mice immunized with the recombinant pro‐
tein of a single TSP-2 subclass showed no protection, while immunization with a mixture of
seven recombinant TSP-2 subclasses provided a moderate protection [66]. A recent study
used S. mansoni TSP-2 extracellular loop 2 region in conjunction with alum and CpG as adju‐
vants leading to extremely variable protection levels against challenge infection within co‐
horts of highly inbred C57BL/6 mice [67]. An S. mansoni stomatin-like protein, a tegument
protein located at the host-parasite interface, engendered in immunized mice a partial pro‐
tection of 30-32%, associated with specific IgG1 and IgG2a antibodies and elevated produc‐
tion of IFN-g and tumor necrosis factor (TNF), while no IL-4 production was detected,
suggesting a Th1-predominant immune response [68]. A schistosomular tegument prepara‐
tion (Smteg) was used for C57BL/6 mice immunization, subcutaneously, on days 0, 15, and
30, resulting in significant antibody production, increased percentage of CD4 + IFN-g+ and
CD4 + IL-10+ cells in spleen and increased production of IFN-g and IL-10 by spleen cells, but
failed to reduce parasite burden, female fecundity and morbidity [69].
Sm23-, tetraspanins-, and other tegument-associated molecules- based protection was ascri‐
bed to specific antibody interaction with the molecules residing at the host-parasite inter‐
face, followed by binding to effector cells, which are able to elicit vigorous complement, and
antibody-dependent cell-mediated cytotoxicity (ADCC) [65,67]. Indeed, ADCC was shown
to be effective in killing a substantial proportion of 3-, 18- and sometimes 24-hr-old schisto‐
somula [70-76], a phenomenon of limited in vivo relevance since larvae of that age still re‐
side in the epidermis, impervious to any immune attack. On the other hand, older larvae,
migrating schistosomula, pre-adut and adult worms surface membrane antigens are inacces‐
sible to antibody binding [77,78], and thus, not threatened by ADCC. According, surface
membrane, like cytosolic, antigens may not be considered for effective vaccination against
schistosome infection.
No vaccine antigens appeared available, while we were striken by the paradox of lung-stage
schistosomula being documented as the target of innate and RA vaccine immunity [1,40],
and obtaining nutrients essentially via the tegument, while their surface membrane are en‐
tirely hidden, inaccessible to specific antibody binding.
3. The enigma of the lung-stage schistosomula
3.1. Lung-stage schistosomula strive without feeding in lung capillaries while surface
membrane molecules are entirely hidden, inaccessible to specific antibody binding
Migrating schistosomula usually do not ingest erythrocytes because of their undersized
mouth [79], and import sugar, fatty acids, and other nutrients directly across their tegument
and into their internal tissues via membrane-spanning transporters [80-82]. Paradoxically,
no specific antibody is able to bind to lung-stage larvae surface membrane antigens, as
judged by several serological tests, namely indirect membrane immunofluorescence
[1,40,77,78,83-89]. We were unable to visualize the presence of the glucose transporter
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SGTP4 on the surface membrane of intact in vitro cultured or ex vivo 5 -7 day-old schistoso‐
mula, using specific antibodies and indirect membrane immunofluorescence [90]. Entire fail‐
ure of larval surface membrane antigen detection does not give support to the contention
that the tegument is bounded externally by a single lipid bilayer, overlain by a laminate se‐
cretion containing numerous proteins and molecular complexes [82,91], and was previously
ascribed to shedding of antigenic molecules [86], masking by host proteins [85,88], or intrin‐
sic biochemical modifications of the outer membrane [77,83,84,87, 89].
3.2. Attempts to expose the lung-stage and adult worm surface membrane antigens to
specific antibody binding
In an attempt to overcome the lack of exposure of S. mansoni and S. haematobium lung stage
larvae apical membrane antigens to specific antibody binding, we started by manipulating
potential cues for increased surface antigenic expression, such as lack of glucose and amino
acids, and extremes of pH or HCO3- concentration. All such trials failed to alter the negligi‐
ble S. mansoni larval reactivity with RA vaccine and infection sera in membrane indirect im‐
munofluorescence (IF). It was then thought that incubation of ex-vivo lung stage
schistosomula in strongly hydrophobic medium might induce exposure of outer surface
membrane hydrophobic sites, where antigenic molecules could be sequestered. Lung-stage
schistosomula were, therefore, incubated with sera diluted in sterile corn oil. It is of note
that corn oil essentially consists of poly- (linoleic acid, 45.9 to 55.5 %), and mono- (olecic
acid, 28.4 to 36.9 %) unsaturated fatty acids, and contains 1 to 2% unsaponifiables particular‐
ly rich in sterols and tocopherols. Schistosoma mansoni [92] and S. haematobium (Figure 1) ex-
vivo lung-stage schistosomula could readily bind specific antibodies of RA vaccine or
infection sera in the fluorescent antibody test, following incubation in corn-oil in a concen‐
tration- and time-dependent manner.
 A B C D 
Figure 1. Assessment of the serological reactivity of S. haematobium lung-stage schistosomula by IF. Seven days ex
vivo larvae incubated with control (A,C) or RA vaccine (B,D) serum diluted 1:50 in RPMI medium, before (A,B) or fol‐
lowing incubation for 6 hr with 90% oil (C,D) were tested in IF and photographed under ultraviolet microscopy. x 200.
Since incubation of lung-stage parasites in corn oil led to exposure of antigenic sites in a con‐
centration and time-dependent fashion, it was suggested that corn oil lipids may mediate ef‐
flux of cholesterol or phospholipids from the worm outer membrane, leading to changes in
lateral diffusion of surface antigens that resulted into a dramatic increase in the avidity of
antibody binding. Treatment with the membrane-impermeable, cholesterol-extracting drug
methyl-b-cyclodextrin (MBCD), followed by visualization of surface membrane cholesterol
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by staining with filipin III, a fluorescent polyene antibiotic, widely used for the detection
and the quantitation of cholesterol in biomembranes, allowed us to examine the role of cho‐
lesterol in surface membrane antigen sequestration of S. mansoni and S. haematobium ex vivo
lung-stage larvae. Evaluation of cholesterol content and distribution by filipin staining dem‐
onstrated that MBCD efficiently extracts cholesterol from the surface membrane of S. manso‐
ni and S. haematobium lung-stage larvae [93,94]. Treatment of S. mansoni ex-vivo lung-stage
larvae with MBCD consistently and reproducibly led to considerable binding of specific an‐
tibodies to the outer membrane surface. The data, thus, suggest that depletion of cholesterol
from the outer membrane of S. mansoni lung-stage schistosomula corrects their failure to
bind antibodies in the fluorescent antibody test. However, S. haematobium larvae treated
with 2.5, 5.0, or 10 mM MBCD were consistently negative following incubation with either
control or RA serum in the fluorescent antibody test. Hence, the results indicated that al‐
most complete depletion of cholesterol from the surface membrane of S. haematobium larvae
did not modify the negligible binding of specific antibodies by the surface membrane anti‐
gens. This means that S. haematobium and S. mansoni ex vivo lung-stage larvae differ regard‐
ing the contribution of cholesterol to the sequestration of surface membrane antigens [93,94].
3.3. Solving the schistosomula lung-stage enigma and predicting the existence of a
parasite tegument-associated neutral sphingomyelinase (nSMase)
The data together strongly supported the contention that antigenic molecules persist on the
surface of ex-vivo lung-stage schistosomula [89-91], yet are entirely inaccessible to specific
antibody binding, in part due to cholesterol sequestration. Surface membrane antigens of S.
mansoni and S. haematobium ex vivo lung schistosomula were, however, readily exposed to
specific antibody binding following incubation in corn oil as mentioned above. It was hy‐
pothesized that corn oil unsaturated fatty acids (FA) might activate parasite surface mem‐
brane-bound neutral sphingomyelinase (nSMase), leading to hydrolysis of surface
membrane sphingomyelin (SM), and subsequent decrease in outer bilayer lipid rigidity and
permeability. At variance from MBCD, incubation of lung-stage schistosomula with unsatu‐
rated FA, such as corn and olive oil, or arachidonic acid (ARA), led to exposure of the, other‐
wise concealed, surface membrane antigens of S. mansoni and S. haematobium alike. In that
respect, S. haematobium appeared more sensitive than S. mansoni, requiring lower unsaturat‐
ed FA concentrations and shorter incubation periods [95, and references therein].
Evaluation of cholesterol amount and distribution by the filipin staining method indicated
that unsaturated FA did not appear to elicit exposure of schistosomular surface membrane
antigens via cholesterol extraction, as previously suggested. While a definite proof needs
and remains to be established, some lines of evidence support the hypothesis that unsaturat‐
ed FA might elicit larval surface membrane antigen exposure via their ability to stimulate a
putative tegument-associated nSMase, with subsequent SM hydrolysis, and access of anti‐
bodies [95,96].
We have been able to demonstrate that 1- intact healthy ex vivo schistosomula, display‐
ing equilibrium in SM synthesis and hydrolysis,  allow molecules of  less than 600 Da to
access their surface membrane molecules. 2- Ex vivo larvae exposed to conditions condu‐
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cive to nSMase inactivation (pH less than 7.2,  high concentrations of nitric  oxide or hy‐
drogen  peroxide),  do  not  allow  neither  antibodies  nor  even  very  small  molecules  (less
than  600  Da)  to  access  their  surface  membrane  molecules  [96].  Sphingomyelin  appears
critical in maintaining the rigidity and impermeability of the parasite outer lipid bilayer,
likely via the ability of hydroxyl and amide groups in the interfacial region of sphingoli‐
pids to form with water molecules a tight netwok of hydrogen bonds [96, and references
therein]. Recently, quasi-elastic and inelastic neutron scattering experiments on S. manso‐
ni  and S. haematobium  worms and larvae have been performed. The obtained experimen‐
tal findings suggest that the larva-medium interaction is triggered by the hydrogen bond
network. Furthermore, the strength of that hydrogen bond network-based interaction ap‐
peared to  be  higher  for  S.  mansoni  larvae than adult  worms and for  S.  mansoni  than S.
haematobium [Federica Migliardo, Unpublished Observations]. 3- Inhibition of ex vivo lar‐
vae SM synthesis or moderate nSMase activation (exposure to low concentrations of un‐
saturated  FA,  especially  ARA)  allows  specific  antibody  access  and  visualization  of
surface membrane antigens. Exposure of ex vivo larvae to conditions conducive to exces‐
sive  nSMase  activation  (hypoxia,  high  concentrations  of  unsaturated  FA,  notably  ARA)
lead to their irreversible attrition [96, and references therein].
3.4. Evidence for the existence of parasite tegument-associated nSMase and its activation
by arachidonic acid
In  2006,  we  predicted,  and provided evidence  for,  the  existence  of  a  schistosome tegu‐
ment-associated  Mg2+-dependent  nSMase,  which  is  able  to  hydrolyze  some  SM  mole‐
cules,  thus  allowing  nutrients,  but  not  host  antibodies,  to  access  proteins  at  the  host-
parasite  interface [96].  Excessive activation of  the elusive nSMase using the unsaturated
FA, ARA led to larval and adult worm surface membrane antigens exposure and eventu‐
al  attrition  [95-97].  The  identification  and  sequence  of  S.  mansoni  putative  nSMase  was
reported  by  Berriman et  al.  in  2009  [98;  Accession  number  XP_002578732.1].  The  mole‐
cule of 70.99 kDa was shown to consist of 631 amino acids (aa) with an N-terminal, 300
aa  Mg++-dependent  exonuclease/endonuclease/  phosphatase  (EEP)  superfamily  catalytic
domain,  and  predicted  7  transmembrane  regions  at  aa  locations  355-377,  392-414,
435-457,  461-483,  527-549,  564-586  and 595-617 (genedb.  org/  gene/  Smp_162880).  The S.
mansoni  putative nSMase showed about  52% homology with the amino terminal  300 aa
of  Mus musculus  and human nSMase 1,  which consists  of  419  and 423  aa,  respectively,
an  exonuclease/endonuclease/phosphatase  superfamily  domain  at  the  N-terminus,  and
two transmembrane domains at the C-terminus.
Using primers based on the published sequence of S. mansoni nSMase, El Halbousy, Tallima,
and El Ridi (personal communication) succeeded in cloning and sequencing 836 bp near the
5’ end of S. haematobium nSMase-encoding mRNA. The predicted aa sequences correspond‐
ed to aa18- aa277 in the S. mansoni counterpart with 96% identities and 98% positives (Figure
2), and contained the conserved domains characterizing the EEP superfamily.
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Figure 2. Homology between predicted amino acid sequences of S. mansoni (SMnSM) and S. haematobium (SHnSM)
neutral sphingomyelinase.
A systematically improved high quality genome and transcriptome of the human blood
fluke S. mansoni was recently reported by Protasio et al. (unpublished observations), where‐
by sequence for S. mansoni putative nSMase was now shown to encode 431 (CCD60196.1)
and not 631 (XP_002578732.1) aa and 100% identity with the latter sequence only for the first
345 aa, as only 2 transmembrane domains were identified near the carboxyl end, between aa
325 and 375.
It is of note that the whole-genome sequence of S. haematobium was recently published [99],
and reported the coding sequence (1038 bp) of an S. haematobium putative neutral sphingo‐
myelinase (http://www.schistodb.net; Sha_103241), encoding 345 aa, with 3 transmembrane
domains at the carboxyl end. Blasting of our SHnSM sequences with Sha_103241 revealed
94-97% homology. However, the sretch of SHnSm aa33-116 (highlighted in Figure 2), which
contained EEP superfamily signature sites and showed complete homology with the S. man‐
soni counterpart, was lacking in Sha_103241 published sequence.
Antibodies specific to S. mansoni nSMase were generated in mice, immunized with peptides
based on the molecule predicted aa sequence, synthesized as multiple antigen peptide
(MAP) constructs. We were able to confirm the presence of the enzyme in adult male and
female S. mansoni and S. haematobium tegument as judged by enzyme-linked immunosorb‐
ent assay (ELISA) and membrane and cytoplasmic IF. We were also the first to measure
nSMase enzymatic activity in Triton X-100-solubilized surface membrane (Sup 1) and whole
worm soluble (SWAP) molecules of male and female S. mansoni and S. haematobium. Neutral,
but no acidic, sphingomyelinase activity was readily detectable by the Amplex Red Sphin‐
gomyelinase Assay, and increased with incubation time and protein amount. The nSMase
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activity of Sup 1 and SWAP of male and female S. mansoni and S. haematobium adult worms
was significantly (P < 0.05 - < 0.0001) increased following exposure to 125 or 250 mM linoleic
acid, ARA, docosahexaenoic acid, or phosphatidyl serine, with ARA consistently showing
the highest nSMase activating potential [100].
4. Arachidonic acid as a remedy for schistosomiasis
Since incubation of S. mansoni and S. haematobium ex vivo larvae [95,96] and adult worms
[97] with ARA leads to exposure of surface membrane antigens and eventual attrition, it was
rational to propose ARA for chemotherapy of schistosomiasis. ARA could be schistosomici‐
dal per se, and additionally would expose the parasite surface membrane molecules to host
antibodies-mediated attack, thus eliciting drug and immune system synergy.
In  our  studies,  pure  ARA  from  Sigma  was  used  for  in  vitro  and  preliminary  in  vivo
studies,  while ARA from Martek was used for in vivo studies [101,102].  We have dem‐
onstrated that 5 mM pure ARA (Sigma) leads to irreversible killing of ex vivo larval, ju‐
venile,  pre-adult  and  adult  S.  mansoni  and  S.  haematobium  worms,  within  1-  5  hr,
depending  on  the  parasite  age,  and  the  fetal  calf  serum  concentration.  ARA-mediated
worm attrition was prevented by nSMase inhibitors such as CaCl2 and GW4869. Electron
microscopy studies revealed entire disruption of the outer lipid bilayers,  the strength of
which correlated with ARA concentration. These consistent and reproducible findings in‐
dicate that ARA is schistosomicidal per se [101].
ARA-mediated S. mansoni and S. haematobium worm in vitro attrition was reproduced in
vivo whereby a series of 20 independent experiments, using BALB/c or C57BL/6 mice or Sy‐
rian hamsters, indicated that oral administration of 300-2500 mg/kg ARA in a pure form
(Sigma), included in infant formula (Nestle), or capsules (X Factor, Molecular Nutrition), on
2 consecutive days, consistently led to between 50 and 80% decrease in S. mansoni or S. hae‐
matobium worm burden [101,102]. ARA-mediated attrition in vivo appeared to be associated
with high titers of serum antibodies to tegumental antigens, because it was significantly
higher when treatment was started at 8, rather than 5 or 6, week post infection with S. man‐
soni. Immune responses to adult worm tegumental antigens are certainly powerful in adults
and children with patent or chronic schistosomiasis, and ARA is already marketed for hu‐
man use in USA and Canada for proper development of newborns, and muscle growth of
athletes. Accordingly, it is recommended to start pre-clinical and clinical studies in human
volunteers for development of ARA as a safe and cost-effective remedy to schistosomiasis,
especially that no ARA-related adverse effects were seen in any experiment in mice or ham‐
sters [101-103].
5. Larval excretory-secretory products as vaccine candidates
Schistosome cytosolic and surface membrane antigens are entirely hidden, inaccessible to
the host immune system effectors. As spelled out by Patrick Skelly [104], “schistosomes
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have achieved invisibility“, and if it were not for the parasite “scent“, the excretory-secreto‐
ry products (ESP), a schistosomiasis vaccine would be as good as over.
Excretory-secretory products of cercariae,  in vitro cultured and ex vivo lung-stage schis‐
tosomula, and adult worms of S. mansoni, S. japonicum  [8,17,105-111], and S. haematobium
as well [99] have been identified in several studies, and were found to be dominated by
actin,  enolase,  aldolase,  GST,TPI,  glyceraldehyde-3 phosphate dehydrogenase (SG3PDH),
thioredoxin peroxidease (TPX) = peroxyredoxin, proteases, and calcium-binding proteins,
namely calpain.
Cercarial ESP would activate innate immune cells in the epidermis and dermis
[8-11,111-117], but would not be targeted by antibody or complement products in the blood-
and lymph-free epidermis. In the dermis, larval ESP may interact with host innate effectors,
such as natural antibodies, serum lectins and complement components, resulting into in‐
flammation that would facilitate the parasite entry into dermal blood capillaries. Schistoso‐
mula then migrate via the venous system in relatively large vessels, whereby ESP are
quickly “washed“ away by neutrophils and monocytes. In contrast, lung-stage larvae ESP
likely stagnate in the narrow, convoluted, and notably thin-walled lung capillaries and liver
sinusoids. These sites are the most strenuous of the journey, an occasion for the parasite to
get rid of the less fit “members“, and an explanation for the lung-stage and pre-adult larvae
being documented as the target of innate and acquired resistance to schistosomiasis [1,118].
Adult worms reside in vessels, which are neither narrow nor thin-walled, and accordingly,
the large ESP amounts they release are rapidly pinocytosed or phagocytosed, and transport‐
ed away from the worms for stimulation of rather innocuous immune responses in the
spleen, the principal target for intravascular antigens.
6. The plausible mechanism of innate and immune attrition of invading
larvae
Migrating larvae ESP presented by blood monocytes and dendritic cells trigger Th lympho‐
cytes in host spleen for production of predominantly Th1 (IFN-g and TNF) and Th17 (IL-17)
cytokines [14,15,17-19], especially if the host was previously RA-vaccinated [16,118] or im‐
munized with vaccine candidate antigens in conjunction with Th1 adjuvants [62-68]. Addi‐
tionally, larval ESP- antibody complexes may activate immune effector cells via FcR
binding. Stimulated monocytes produce nitric oxide and reactive oxygen products [119],
which are lethal to near-by schistosomules; however, these toxic molecules inhibit the para‐
site tegument-associated nSMase activity, leading to outer membrane entire impermeability
[95,96,120,121]. Neutrophils recruited and activated by Th17 cytokines likely ensnare larvae
in their extracellular traps, yet secrete proteases and other enzymes that might all be ineffec‐
tive because of the worm tight lipid bilayer and inaccessibility of surface membrane mole‐
cules [119,122,123].
Eosinophils also produce extracellular traps, and their basic molecules would be severely
toxic to captured schistomula [124,125]. Basophils release cytotoxic basic molecules, and
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most importantly, pharmacologic mediators able to modulate endothelial integrity, thus en‐
couraging larvae to escape extravascularly to a certain demise [126]. Indeed, that attrition
mechanism was shown to be of great importance in resistance to challenge infection in the
RA model [118]. However, eosinophils and basophils are recruited and activated by type 2
cytokines [125,126], and thus, are prevented from active participation in the hunt for devel‐
oping larvae [1,19] following infection of naive and antigens/Th1 adjuvant-immunized mice.
Nevertheless, attempts to vaccinate mice against schistosomiasis uniformly aim at enhanc‐
ing Th1 immune responses, in spite of the documented role of Th2 cytokines, namely IL-4,
in protection of RA immunized mice [127-130]. Also in rats, sterile resistance to S. mansoni is
associated with production of IL-4, IL-5, and IL-13, while susceptibility is accompanied with
elevated expression of IFN-g [131,132 ]. In humans, a good association was previously ob‐
served between serum IgE production and resistance to infection after chemotherapy
[41-43]. Indeed, Fallon et al. [133] reported that “adult resistance and child susceptibly to re‐
infection after chemotherapy have been described for all 3 Schistosoma species that most
commonly infect man. For all 3 parasite species, the immunological correlates of this age-
dependent resistance are associated with type 2 responses“. These findings were entirely
confirmed in recent studies [134-136].
7. The road to a sterilizing schistosomiasis vaccine
Larval ESP are innumerable, among which we have selected those eliciting the weakest Th1
and Th17 responses, namely SG3PDH in a recombinant (rSG3PDH) form and a TPX MAP
construct [19,110]. Nevetheless, it was critical to use an adjuvant that would skew the larval
immune responses towards the Th2 axis. In contrast to incomplete Freund’s adjuvant, alum,
polyinosinic-polycytidylic acid, and peptidoglycan, the Th2 master cytokine, thymic stromal
lymphopoietin (TSLP), succeeded in directing the ESP-mediated immune responses towards
a Th2-biased profile in prototypical Th1 (C57BL/6) and Th2 (BALB/c) mice [110,137]. There‐
after, we have immunized outbred, akin to humans, mice with rSG3PDH and TPX MAP in
conjunction with the type 2 cytokines, TSLP, IL-25, or IL-33 [138, and references therein]. Re‐
sults of 8 independent experiments indicated that these formulations elicited IgM, IgG1, and
IgA specific antibodies, and an increase in ex vivo spleen cells release of IL-4, IL-5, and IL-13
correlated with consistent, reproducible, and highly significant (P < 0.0001) reduction of 62%
to 78% in challenge S. mansoni worm burden [138]. Similar studies using S. haematobium are
now in progress.
8. Conclusion
Improved selection of larval ESP, singly or in a mixture, and type 2 adjuvant is expected to
result into a sterilizing vaccine against schistosome infection. Concurrent development of
ARA, a nutrient, a component of our cell membranes, for chemotherapy of infection in un‐
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immunized individuals, will likely lead to full control, and eventual elimination of schisto‐
somiasis.
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